Alnylam Pharmaceuticals
Diana Cha is an accomplished professional with a diverse background in bioanalytical sciences. Currently serving as Associate Director and Principal Scientist at Alnylam Pharmaceuticals since January 2020, Diana leads a bioanalytical group focused on molecular, LBA, and biomarker bioassays in Early Development. Responsibilities include interfacing with chemistry and research teams, overseeing method development and qualification for pre-clinical assays, and managing projects and timelines. Previous experience includes roles as Senior Scientist and Scientist at Amgen, where Diana developed and validated target engagement biomarkers in neuroinflammation, and a Research Fellow at Brigham and Women's Hospital, focusing on Alzheimer's disease biomarkers. Diana also holds a Ph.D. from Vanderbilt University School of Medicine and a B.Sc. in Biology, Physiology from the University of Washington, complementing a strong foundation in biomedical research.